NVS - Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish Sees 100% Upside | Benzinga
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis AG's (NYSE: NVS) Pluvicto, providing an influx of capital from strategic ventures and new company establishments.
This validates mergers and acquisitions as major players seek fresh Radiopharmaceutical Therapy (RPT) capabilities to craft distinctive oncology platforms.
RBC analysts note that Fusion is competitively positioned based on its proprietary target alpha therapy platform, diverse pipeline, deep radiopharma pedigree, and established manufacturing expertise, which are key to commercial success.
The analysts initiated with an Outperform (Speculative Risk)